About Exo Therapeutics
Exo Therapeutics is a small molecule drug discovery and development company with technology to address intractable pharmaceutical targets. By leveraging the company’s ExoSight platform, Exo is developing a deep pipeline of potent drug candidates that bind exosites, distal and unique binding pockets that have the potential to reprogram enzyme activity for precise and robust therapeutic effect.
Missing: Exo Therapeutics's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Exo Therapeutics's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Research containing Exo Therapeutics
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned Exo Therapeutics in 1 CB Insights research brief, most recently on Jan 19, 2021.
Expert Collections containing Exo Therapeutics
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Exo Therapeutics is included in 1 Expert Collection, including Biopharma Tech.
Latest Exo Therapeutics News
Jun 10, 2022
Japanese and US venture capital specialists have invested $50 million in Series A growth finance to fuel expansion at Transition Bio, which has operations in Cambridge, Massachusetts and Cambridge UK. The microfluidics-driven drug discovery platform company is using biophysical sciences and AI tools to map and modulate biomolecular condensates. The Series A has been led by Northpond Ventures (Maryland), with participation from Taiho Ventures (Japan), Bristol Myers Squibb (New York), Lifeforce Capital and Magnetic Ventures – both based in San Francisco. Greg Miller, chief executive officer of Transition Bio, said: “We are excited to have such a high-quality group of investors alongside us as we apply and expand our one-of-a-kind predictive approach to analysing and modulating biomolecular condensates. “The technology and tools we have built – and the data we are generating – are unmatched in capability and scale, and the pace and depth of our progress across all areas of the company has been extraordinary. Our team is uniquely suited to harness the fundamental and largely untapped biology of condensates which is at the centre of many disease pathways.” The money will accelerate the progress made to date with the company’s novel Condensomics™ platform. This utilises microfluidics to drive high-throughput generation of proprietary data to enable machine learning-guided condensate target identification and drug discovery. The funding allows rapid expansion of the technology by scaling up the platform and translating the science across a variety of targets and disease areas. In addition, Shilpi Arora joined Transition Bio as senior vice-president of discovery research and brings extensive experience in leading multiple aspects of drug discovery, target identification and validation, pharmacology and translational sciences from previous roles in both academia and the biotech industry. Prior to joining Transition Bio, Shilpi was vice-president of discovery and translational biology at Exo Therapeutics and previously held roles at X-Chem Pharmaceuticals, Constellation Pharmaceuticals and the Translational Genomics Research Institute. Shaan C. Gandhi – director and head of the biotechnologies group at Northpond Ventures – has been appointed to the company’s board. Alfred W. Sandrock, Jr., chief executive officer of Voyager Therapeutics and former head of research and development at Biogen, has become an independent director. Co-founders Kelly Martin and Samuel Cohen, will continue to serve on the board as executive chairman and director, respectively. “On behalf of the founders, we are delighted and amazed by how far the team has come in such a short period of time,” said Martin. “This financing is a testament both to the underlying scientific foundation, created through the tremendous work and innovation of Dave Weitz and Tuomas Knowles over the past decade, as well as to the talented team of dedicated and enthusiastic professionals working with us in the US, UK and beyond.” Transition Bio launched in September 2020 with a seed round led by Lifeforce Capital. The microfluidics-driven drug discovery platform company is working to establish a one-of-a-kind technology platform to revolutionise condensate drug discovery. With a physics-first approach that enables proprietary data generation that in turn maps condensate behaviour on an unprecedented scale, it aims to be the leading technology and data-driven company in the new and rapidly expanding field of condensate cell biology. Related Articles
Exo Therapeutics Web Traffic
Exo Therapeutics Rank
Exo Therapeutics Frequently Asked Questions (FAQ)
When was Exo Therapeutics founded?
Exo Therapeutics was founded in 2018.
Where is Exo Therapeutics's headquarters?
Exo Therapeutics's headquarters is located at 480 Arsenal Way, Watertown.
What is Exo Therapeutics's latest funding round?
Exo Therapeutics's latest funding round is Series B.
How much did Exo Therapeutics raise?
Exo Therapeutics raised a total of $103M.
Who are the investors of Exo Therapeutics?
Investors of Exo Therapeutics include Novartis Venture Funds, CRV, 6 Dimensions Capital, Newpath Partners, BVF Partners and 6 more.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.